Why Barrière Thinks You’ll Want To Wear You Vitamins
Barrière, a wearable vitamin patch company, is expanding into 1,700 Walmart stores and projects $10 million in 2026 revenue. The company claims its transdermal patches deliver supplements through the skin directly into the bloodstream, though experts note clinical evidence for this delivery method is largely lacking. The brand targets younger consumers with stylish, trendy packaging while navigating a largely unregulated supplement industry.
Summary
Barrière is a wearable supplement patch company operating in the $60 billion dietary supplement market, which features around 100,000 products. The company delivers vitamins and herbal ingredients transdermally — through the skin and into the bloodstream — activated by body heat. After a successful test run in about 50 Walmart locations, Barrière announced an exclusive partnership with Walmart to expand into 1,700 stores, bringing its total retail presence to over 6,000 stores. The company projects its 2026 revenue will more than double its 2025 revenue, reaching $10 million, with a current valuation of $19 million.
Barrière's product lineup includes patches for nausea (formulated with ginger, peppermint, and B6), motion sickness, and notably, a lactose intolerance relief patch — which the company claims is the first of its kind in the world. Products retail between $13 and $18. The brand cites rising health consciousness among younger consumers, fueled by social media platforms like TikTok and Instagram, as a key driver of demand. The broader cultural context includes the Make America Healthy Again movement and RFK Jr.'s declaration that the FDA would end its 'war on vitamins.'
Despite the company's growth, experts raise concerns about the clinical efficacy of transdermal supplement delivery. A medical expert interviewed noted that the assumption that small molecules will penetrate skin and achieve bioavailability lacks strong clinical evidence, contrasting it with well-documented oral supplementation studies. Barrière's own clinical trial involved only 30 subjects and lacked a control group. The CEO acknowledged that rigorous clinical trials have been cost-prohibitive and are not legally required to sell supplements in the US, but stated the company plans to pursue them within 3 to 5 years.
The regulatory environment compounds these concerns. Under the Dietary Supplement Health and Education Act of 1994, supplements are classified as food products rather than pharmaceuticals, leaving product safety largely up to companies. A survey found that 48% of consumers incorrectly believe the FDA regulates supplements the same way as prescription drugs. Barrière attempts to differentiate itself through transparency and quality measures: its products are manufactured in the UK at FDA-equivalent regulated facilities and tested in third-party labs, neither of which is legally required. The company frames its mission as solving not just biological efficacy, but the behavioral challenge of helping consumers maintain healthy daily habits.
Key Insights
- Barrière's CEO acknowledges that rigorous clinical trials are cost-prohibitive and not legally required to sell supplements in the US, and the one trial the company conducted had only 30 subjects and no control group.
- A medical expert argues that clinical evidence for transdermal supplement bioavailability is lacking, and that oral supplementation has documented studies showing it corrects nutrient deficiencies — whereas a patch with vitamin D, for example, does not have comparable evidence.
- Barrière claims to have created the first lactose relief patch in the world, positioning it as a one-patch-a-day solution for all-day dairy freedom.
- A medical expert contends that marketing is usually way ahead of science in the supplement industry, and that consumers are choosing convenience over clinical efficacy with products like wearable patches.
- Nearly half of survey respondents — 48% — incorrectly believe the FDA regulates dietary supplements the same way as prescription drugs, reflecting a widespread misunderstanding of the supplement industry's largely self-regulated nature.
Topics
Transcript
[0:00] Young people are prioritizing their health, and it's showing up on company balance sheets. The dietary supplement market is a highly competitive $60 billion industry, with around 100,000 products available to consumers. And a new way to take these supplements is emerging in the market. Wearable patches. Barriére is one of the companies leading the charge. It told CNBC exclusively that it's partnered with Walmart to roll out its products in 1700 stores after a successful test run in about 50 Walmart locations last year. The company projects [0:31] its 2026 revenue to more than double 2025 revenue and reach $10 million, with a current valuation of $19 million. As of today, we are in over 6000 stores, with…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
How Twilio and Datadog are winning back investors
Twilio and Datadog are outperforming the software industry by leveraging AI-native solutions and demonstrating clear monetization paths. Both companies have seen significant stock gains (45% and 60% respectively in one month) as they successfully partner with rather than compete against major AI companies.
How Barrière is trying to disrupt the supplement industry
Barrière is disrupting the supplement industry with transdermal vitamin patches, partnering with Walmart to expand from 50 to 1,700 stores. The company projects 2026 revenue to exceed $10 million with a current $19 million valuation, though expert skepticism remains about the clinical efficacy of patch-based delivery versus established oral supplements.
CNBC takes Tesla's Grok for an NYC drive
CNBC tests Tesla's Grok AI navigation system during an NYC drive, where Grok makes an incorrect turn onto West 57th Street instead of continuing straight on Broadway. The segment highlights concerns about over-reliance on AI navigation in complex urban environments and also demonstrates Grok's willingness to engage in adult-oriented conversations without content restrictions.
How Snack Companies Could Lose Millions Of Dollars Over ‘MAHA’ Laws
New SNAP restrictions inspired by Robert F. Kennedy Jr.'s MAHA movement are limiting purchases of sugary drinks and candy, with over 20 states implementing these rules affecting nearly one-third of SNAP participants. Food companies face potential losses of $830 million this year as they scramble to understand changing consumer behavior and reformulate products to comply with new regulations.
Former Disney CEO Bob Iger On What China Has Meant For The Company
Former Disney CEO Bob Iger reflects on the 10th anniversary of Shanghai Disneyland, discussing its success, the evolution of Chinese consumers, and Disney's investment plans in China. He also shares thoughts on AI, geopolitical risks, and his philosophy of bold risk-taking as foundational to Disney's identity.